[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse APLP1

Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: C30: Cytoplasm. Note=C-terminally processed in the Golgi complex.
Domain PF10515 beta-amyloid precursor protein C-terminus
PF12924 Copper-binding of amyloid precursor
PF12925 E2 domain of amyloid precursor protein
PF02177 Amyloid A4 N-terminal heparin-binding
Function

May play a role in postsynaptic function. The C-terminal gamma-secretase processed fragment, ALID1, activates transcription activation through APBB1 (Fe65) binding (By similarity). Couples to JIP signal transduction through C-terminal binding. May interact with cellular G-protein signaling pathways. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I. ; FUNCTION: The gamma-CTF peptide, C30, is a potent enhancer of neuronal apoptosis.

> Gene Ontology
 
Biological Process GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030809 negative regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030818 negative regulation of cAMP biosynthetic process
GO:0045980 negative regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0052652 cyclic purine nucleotide metabolic process
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071867 response to monoamine
GO:0071868 cellular response to monoamine stimulus
GO:0071869 response to catecholamine
GO:0071870 cellular response to catecholamine stimulus
GO:0071873 response to norepinephrine
GO:0071874 cellular response to norepinephrine stimulus
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900372 negative regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0031690 adrenergic receptor binding
GO:0031694 alpha-2A adrenergic receptor binding
GO:0031695 alpha-2B adrenergic receptor binding
GO:0031696 alpha-2C adrenergic receptor binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between APLP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of APLP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of APLP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2070.132
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3360.316
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1370.381
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8340.0208
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7780.505
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9030.524
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7560.242
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3980.673
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.3470.167
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5440.285
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4610.489
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.10.623
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of APLP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APLP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APLP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APLP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APLP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of APLP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between APLP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAPLP1
Nameamyloid beta (A4) precursor-like protein 1
Aliases APLP; amyloid-like protein 1; amyloid precursor-like protein 1; APLP-1
Chromosomal Location19q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting APLP1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting APLP1.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141